Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

DQDavid QuallsOFOmnia FarahatAAAmy Ayers

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows progression-free survival in large B cell lymphoma with CD20 therapy, indicating diverse treatment options.

Key Points

  • Overall response rate to CAR T reported at 73% after bispecific antibody therapy in 15 evaluable patients.
  • Median follow-up time after CAR T therapy was 3.6 months, with cytokine release syndrome observed in 75% of patients.
  • Multivariable analysis indicates that timing between therapies affects efficacy outcomes, highlighting important treatment considerations.
  • This real-world study emphasizes the need for larger investigations into the sequencing of therapies for optimal clinical outcomes.

Cite This Study

Qualls et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e405https://doi.org/10.1182/blood-2025-3663
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium2025
  2. 2Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy2025 · 1 citations
  3. 3Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need2025
  4. 4Real-world comparative outcomes of CAR-T cell therapy versus bispecific antibodies in patients with diffuse large B-cell lymphoma2025
  5. 5Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis2025